Blog
RSS FeedPosted by Michael Wonder on 08 Sep 2023
Review of cancer related surrogate outcomes used for PBAC decision-making
8 September 2023 - Surrogate outcome measures have an increasingly important role in cancer medicine research providing evidence to support ...
Posted by Michael Wonder on 28 Aug 2023
Efficient Funding of Chemotherapy Review – final report
28 August 2023 - The final report of the Efficient Funding of Chemotherapy Review is now available. ...
Posted by Michael Wonder on 18 Aug 2023
Estimating overall survival in people receiving PBS listed cancer medicines in Australian clinical practice
18 August 2023 - In September 2021, the Department of Health and Aged Care contracted the Medicines Intelligence Centre for ...
Posted by Michael Wonder on 15 Aug 2023
New treatments for people with chronic migraine and soft tissue sarcoma added to the PBS
14 August 2023 - From August 2023, Australians with chronic migraine and soft tissue sarcoma will have access to new ...
Posted by Michael Wonder on 01 Aug 2023
Global sarcoma therapy now listed on Pharmaceutical Benefits Scheme
31 July 2023 - Yondelis (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine. ...
Posted by Michael Wonder on 31 Jul 2023
Schedule of Pharmaceutical Benefits - 1 August 2023
1 August 2023 - The August 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 28 Jun 2023
Breast cancer survivor wants $7,000 a month wonder drug to be more readily available to patients
23 June 2023 - A young Wollongong mother has spoken about her "remarkable" recovery from a breast cancer that had ...
Posted by Michael Wonder on 05 Jun 2023
New treatments for Australians with endometrial cancer and Lennox-Gastaut syndrome
5 June 2023 - From 1 June 2023, Australians with endometrial cancer and Lennox-Gastaut syndrome will have access to new ...
Posted by Michael Wonder on 01 Jun 2023
Antengene announces Xpovio plus bortezomib and dexamethasone included for reimbursement by the PBS in Australia for the treatment of relapsed and/or refractory multiple myeloma
31 May 2023 - This inclusion by the PBS for the treatment of patients with relapsed and/or refractory multiple myeloma who ...
Posted by Michael Wonder on 25 May 2023
Australians battling with prostate cancer to benefit from new PBS listing
25 May 2023 - Australians battling prostate cancer that has spread past the prostate will soon benefit from subsidised medicine ...
Posted by Michael Wonder on 21 May 2023
Is the quality of evidence in health technology assessment deteriorating over time? A case study on cancer drugs in Australia.
18 May 2023 - This study aimed to assess whether there have been changes in the quality of clinical evidence ...
Posted by Michael Wonder on 16 Apr 2023
Price of a life: Australians wait two years longer for breakthrough medicines than US citizens
16 April 2023 - Australians are waiting two years longer to access new lifesaving subsidised medicines because of pharma giants. Now, ...
Posted by Michael Wonder on 16 Apr 2023
Australian cancer patients spend $200 million a year on treatments not on the PBS and it’s got to change
16 April 2023 - Australian cancer patients were spending in excess of $200m each year of their own money on therapies ...
Posted by Michael Wonder on 31 Jan 2023
Call for Enhertu to be registered on Pharmaceutical Benefits Scheme
31 January 2023 - Sarah Lee has been forced to use her super and life insurance to pay for the treatment. ...
Posted by Michael Wonder on 03 Dec 2022
Hopes $55k breast cancer drug Keytruda will get PBS listing
3 December 2022 - Women with triple negative breast cancer have been given new hope that immunotherapy drug Keytruda will ...